Cushing's Syndrome: Update on Signs, Symptoms and Biochemical Screening
Overview
Authors
Affiliations
Endogenous pathologic hypercortisolism, or Cushing's syndrome, is associated with poor quality of life, morbidity, and increased mortality. Early diagnosis may mitigate against this natural history of the disorder. The clinical presentation of Cushing's syndrome varies, in part related to the extent and duration of cortisol excess. When hypercortisolism is severe, its signs and symptoms are unmistakable. However, most of the signs and symptoms of Cushing's syndrome are common in the general population (e.g., hypertension and weight gain) and not all are present in every patient. In addition to classical features of glucocorticoid excess, such as proximal muscle weakness and wide purple striae, patients may present with the associated comorbidities that are caused by hypercortisolism. These include cardiovascular disease, thromboembolic disease, psychiatric and cognitive deficits, and infections. As a result, internists and generalists must consider Cushing's syndrome as a cause, and endocrinologists should search for and treat these comorbidities. Recommended tests to screen for Cushing's syndrome include 1 mg dexamethasone suppression, urine free cortisol, and late night salivary cortisol. These may be slightly elevated in patients with physiologic hypercortisolism, which should be excluded, along with exogenous glucocorticoid use. Each screening test has caveats and the choice of tests should be individualized based on each patient's characteristics and lifestyle. The objective of this review is to update the readership on the clinical and biochemical features of Cushing's syndrome that are useful when evaluating patients for this diagnosis.
Alkan S, Guney S, Akcura C, Ozdemir N, Hekimsoy Z Endocrine. 2025; .
PMID: 39864048 DOI: 10.1007/s12020-025-04170-6.
Newell-Price J, Fleseriu M, Pivonello R, Feelders R, Gadelha M, Lacroix A J Endocr Soc. 2024; 9(1):bvae201.
PMID: 39610378 PMC: 11604051. DOI: 10.1210/jendso/bvae201.
Who and how to screen for endogenous hypercortisolism in patients with mood disorders.
Ferrante E, Simeoli C, Mantovani G, Pivonello R J Endocrinol Invest. 2024; .
PMID: 39531206 DOI: 10.1007/s40618-024-02457-5.
Zhao X, Zhou J, Lyu X, Li Y, Ma L, Liu Y Sci Rep. 2024; 14(1):23557.
PMID: 39384846 PMC: 11464552. DOI: 10.1038/s41598-024-74452-y.
Glucocorticoids-based prodrug design: Current strategies and research progress.
Liu H, Ji M, Xiao P, Gou J, Yin T, He H Asian J Pharm Sci. 2024; 19(3):100922.
PMID: 38966286 PMC: 11222810. DOI: 10.1016/j.ajps.2024.100922.